Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Penile Neoplasms | 33 | 2020 | 163 | 4.380 |
Why?
|
Carcinoma, Squamous Cell | 33 | 2020 | 4004 | 1.610 |
Why?
|
Carcinoma in Situ | 9 | 2020 | 794 | 0.890 |
Why?
|
Penis | 6 | 2011 | 211 | 0.760 |
Why?
|
Precancerous Conditions | 11 | 2020 | 969 | 0.570 |
Why?
|
Lichen Sclerosus et Atrophicus | 5 | 2020 | 28 | 0.550 |
Why?
|
Papillomavirus Infections | 9 | 2019 | 1594 | 0.470 |
Why?
|
Condylomata Acuminata | 5 | 2019 | 76 | 0.460 |
Why?
|
Anti-Inflammatory Agents | 2 | 2011 | 1791 | 0.370 |
Why?
|
Skin Neoplasms | 8 | 2018 | 5726 | 0.370 |
Why?
|
Micrococcaceae | 1 | 2010 | 8 | 0.360 |
Why?
|
Melanoma | 10 | 2018 | 5620 | 0.350 |
Why?
|
Papillomaviridae | 4 | 2019 | 1102 | 0.330 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2008 | 49 | 0.320 |
Why?
|
Trypanocidal Agents | 3 | 2015 | 40 | 0.320 |
Why?
|
Aluminum | 1 | 2008 | 152 | 0.310 |
Why?
|
Pathology, Clinical | 2 | 2020 | 367 | 0.310 |
Why?
|
Dermatitis | 1 | 2010 | 200 | 0.310 |
Why?
|
Nitroimidazoles | 3 | 2015 | 112 | 0.300 |
Why?
|
Trypanosoma cruzi | 4 | 2015 | 199 | 0.280 |
Why?
|
Alopecia | 1 | 2011 | 413 | 0.270 |
Why?
|
Granuloma | 1 | 2008 | 325 | 0.270 |
Why?
|
Antibodies, Monoclonal | 6 | 2014 | 9101 | 0.270 |
Why?
|
Cicatrix | 2 | 2010 | 769 | 0.260 |
Why?
|
Urethral Neoplasms | 1 | 2005 | 37 | 0.260 |
Why?
|
Chagas Disease | 3 | 2013 | 164 | 0.250 |
Why?
|
Peripheral Nerves | 1 | 2008 | 466 | 0.240 |
Why?
|
Tumor Virus Infections | 1 | 2007 | 438 | 0.240 |
Why?
|
Clinical Protocols | 1 | 2010 | 1436 | 0.230 |
Why?
|
Neprilysin | 1 | 2007 | 464 | 0.230 |
Why?
|
Phimosis | 1 | 2003 | 10 | 0.220 |
Why?
|
Urethra | 1 | 2005 | 404 | 0.220 |
Why?
|
Bacteremia | 1 | 2010 | 977 | 0.220 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2016 | 219 | 0.210 |
Why?
|
Carcinoma, Basosquamous | 2 | 2012 | 7 | 0.210 |
Why?
|
Skin | 4 | 2010 | 4421 | 0.210 |
Why?
|
Papillomavirus Vaccines | 1 | 2008 | 482 | 0.210 |
Why?
|
Psoriasis | 1 | 2010 | 923 | 0.200 |
Why?
|
Endemic Diseases | 2 | 2012 | 186 | 0.180 |
Why?
|
Balanitis Xerotica Obliterans | 1 | 2020 | 2 | 0.180 |
Why?
|
Antigens, Neoplasm | 2 | 2011 | 1989 | 0.180 |
Why?
|
Lymphatic Metastasis | 6 | 2017 | 2924 | 0.180 |
Why?
|
Skin Diseases | 1 | 2008 | 1083 | 0.170 |
Why?
|
Urogenital Neoplasms | 1 | 2021 | 135 | 0.170 |
Why?
|
Neoplasm Invasiveness | 5 | 2010 | 3585 | 0.160 |
Why?
|
Lymph Nodes | 3 | 2010 | 3474 | 0.160 |
Why?
|
Chagas Cardiomyopathy | 2 | 2015 | 70 | 0.150 |
Why?
|
Biopsy | 4 | 2010 | 6743 | 0.140 |
Why?
|
Immunohistochemistry | 8 | 2020 | 11007 | 0.140 |
Why?
|
Carcinoma, Verrucous | 2 | 2010 | 26 | 0.130 |
Why?
|
Male | 47 | 2021 | 354881 | 0.130 |
Why?
|
Nevus, Pigmented | 1 | 2018 | 215 | 0.130 |
Why?
|
Aged, 80 and over | 20 | 2020 | 58300 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2010 | 9207 | 0.130 |
Why?
|
Carcinoma, Papillary | 2 | 2012 | 782 | 0.130 |
Why?
|
Paraguay | 3 | 2011 | 7 | 0.120 |
Why?
|
Penile Diseases | 1 | 2014 | 45 | 0.120 |
Why?
|
Neoplasm Staging | 4 | 2017 | 11064 | 0.120 |
Why?
|
Middle Aged | 33 | 2020 | 217019 | 0.110 |
Why?
|
Humans | 61 | 2021 | 752341 | 0.110 |
Why?
|
Terminology as Topic | 2 | 2012 | 1527 | 0.110 |
Why?
|
Nifurtimox | 1 | 2013 | 14 | 0.110 |
Why?
|
Neoplasm Metastasis | 3 | 2010 | 4861 | 0.110 |
Why?
|
Diagnosis, Differential | 7 | 2012 | 12898 | 0.110 |
Why?
|
Parakeratosis | 1 | 2012 | 2 | 0.110 |
Why?
|
Antibodies, Protozoan | 2 | 2013 | 247 | 0.100 |
Why?
|
Aged | 26 | 2020 | 166562 | 0.100 |
Why?
|
Foreskin | 1 | 2011 | 31 | 0.100 |
Why?
|
Polymerase Chain Reaction | 6 | 2019 | 6058 | 0.100 |
Why?
|
Nevus | 1 | 2013 | 204 | 0.090 |
Why?
|
Neoplasms, Basal Cell | 1 | 2011 | 31 | 0.090 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2011 | 194 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2007 | 7808 | 0.090 |
Why?
|
Actinomycetales Infections | 1 | 2010 | 30 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2011 | 694 | 0.090 |
Why?
|
Merkel Cells | 1 | 2009 | 24 | 0.090 |
Why?
|
Behcet Syndrome | 1 | 2010 | 86 | 0.080 |
Why?
|
Acantholysis | 1 | 2009 | 11 | 0.080 |
Why?
|
Adult | 23 | 2020 | 216913 | 0.080 |
Why?
|
Cysts | 1 | 2014 | 681 | 0.080 |
Why?
|
Pregnancy Complications, Parasitic | 1 | 2009 | 61 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2011 | 4343 | 0.080 |
Why?
|
Melanocytes | 2 | 2009 | 511 | 0.080 |
Why?
|
Hyperplasia | 3 | 2011 | 1154 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 9355 | 0.080 |
Why?
|
Prognosis | 8 | 2012 | 29327 | 0.080 |
Why?
|
SOXB1 Transcription Factors | 1 | 2009 | 287 | 0.080 |
Why?
|
Keratinocytes | 1 | 2012 | 787 | 0.080 |
Why?
|
Crohn Disease | 2 | 2011 | 2256 | 0.080 |
Why?
|
Melanoma, Amelanotic | 1 | 2007 | 19 | 0.070 |
Why?
|
Point Mutation | 1 | 2013 | 1591 | 0.070 |
Why?
|
In Situ Hybridization | 2 | 2016 | 1896 | 0.070 |
Why?
|
Cytoplasm | 1 | 2012 | 1520 | 0.070 |
Why?
|
Pathology, Molecular | 2 | 2021 | 331 | 0.070 |
Why?
|
Opportunistic Infections | 1 | 2010 | 377 | 0.070 |
Why?
|
Plasma Cells | 1 | 2010 | 588 | 0.070 |
Why?
|
Drug Therapy | 1 | 2010 | 499 | 0.070 |
Why?
|
Lipodystrophy | 1 | 2007 | 145 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3781 | 0.060 |
Why?
|
Young Adult | 9 | 2020 | 57629 | 0.060 |
Why?
|
Head and Neck Neoplasms | 2 | 2010 | 2868 | 0.060 |
Why?
|
Eosinophils | 1 | 2010 | 945 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1686 | 0.060 |
Why?
|
Autopsy | 1 | 2009 | 1006 | 0.060 |
Why?
|
Circumcision, Male | 2 | 2004 | 148 | 0.060 |
Why?
|
Keratosis | 1 | 2005 | 80 | 0.060 |
Why?
|
Genes, Neoplasm | 1 | 2007 | 372 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 2010 | 854 | 0.060 |
Why?
|
Scalp | 1 | 2007 | 383 | 0.060 |
Why?
|
Metaplasia | 1 | 2005 | 319 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2011 | 1324 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2008 | 723 | 0.060 |
Why?
|
Survival Analysis | 2 | 2007 | 10177 | 0.060 |
Why?
|
Societies, Medical | 2 | 2020 | 3833 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2007 | 592 | 0.060 |
Why?
|
Genotype | 5 | 2019 | 12869 | 0.060 |
Why?
|
Epithelium | 2 | 2005 | 1606 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2018 | 19894 | 0.060 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2007 | 587 | 0.050 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2005 | 419 | 0.050 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2007 | 484 | 0.050 |
Why?
|
Antigens, CD | 2 | 2011 | 3908 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2899 | 0.050 |
Why?
|
Consensus | 1 | 2010 | 3034 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2011 | 4495 | 0.050 |
Why?
|
Argentina | 2 | 2012 | 244 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7399 | 0.040 |
Why?
|
Female | 18 | 2015 | 386053 | 0.040 |
Why?
|
Risk Factors | 3 | 2017 | 73412 | 0.040 |
Why?
|
Down-Regulation | 1 | 2007 | 2910 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3599 | 0.040 |
Why?
|
World Health Organization | 2 | 2018 | 1294 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2008 | 1145 | 0.040 |
Why?
|
Valine | 1 | 2000 | 408 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1391 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11266 | 0.040 |
Why?
|
Piperazines | 1 | 2008 | 2486 | 0.040 |
Why?
|
Skin Aging | 1 | 1998 | 133 | 0.030 |
Why?
|
Adolescent | 8 | 2020 | 86765 | 0.030 |
Why?
|
United States | 2 | 2017 | 71442 | 0.030 |
Why?
|
Pyrimidines | 1 | 2008 | 2978 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2010 | 15130 | 0.030 |
Why?
|
Human papillomavirus 18 | 1 | 2016 | 126 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2796 | 0.030 |
Why?
|
Recurrence | 1 | 2007 | 8420 | 0.030 |
Why?
|
Urology | 1 | 2020 | 420 | 0.030 |
Why?
|
Tetrazoles | 1 | 2000 | 888 | 0.030 |
Why?
|
Epitopes | 2 | 2011 | 2496 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2010 | 3750 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2009 | 8422 | 0.030 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 266 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2000 | 1002 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2011 | 1758 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2001 | 798 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2010 | 3589 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11586 | 0.030 |
Why?
|
Insulin | 1 | 2007 | 6569 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 279 | 0.030 |
Why?
|
Comorbidity | 1 | 2007 | 10475 | 0.030 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2013 | 102 | 0.030 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 142 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2009 | 8931 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2495 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2007 | 12738 | 0.020 |
Why?
|
Face | 1 | 1998 | 1011 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2011 | 64 | 0.020 |
Why?
|
DNA, Protozoan | 1 | 2012 | 227 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2011 | 211 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2000 | 2037 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2014 | 4880 | 0.020 |
Why?
|
Laser Therapy | 1 | 1998 | 1092 | 0.020 |
Why?
|
Antigens, Protozoan | 1 | 2013 | 312 | 0.020 |
Why?
|
Interleukin-15 | 1 | 2011 | 183 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 16736 | 0.020 |
Why?
|
France | 1 | 2011 | 504 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14586 | 0.020 |
Why?
|
Treatment Outcome | 6 | 2014 | 64245 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2635 | 0.020 |
Why?
|
Chronic Disease | 2 | 2015 | 9158 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 631 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2011 | 792 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1060 | 0.020 |
Why?
|
Chymases | 1 | 2007 | 73 | 0.020 |
Why?
|
Neoplasm Seeding | 1 | 2008 | 85 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2011 | 945 | 0.020 |
Why?
|
Cromolyn Sodium | 1 | 2007 | 82 | 0.020 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2008 | 100 | 0.020 |
Why?
|
Immunity, Humoral | 1 | 2011 | 594 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2010 | 6781 | 0.020 |
Why?
|
Genetic Testing | 1 | 2020 | 3505 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2008 | 8892 | 0.020 |
Why?
|
Tryptases | 1 | 2007 | 177 | 0.020 |
Why?
|
Arm | 1 | 2009 | 582 | 0.020 |
Why?
|
Stem Cell Niche | 1 | 2009 | 344 | 0.020 |
Why?
|
Nasal Mucosa | 1 | 2009 | 411 | 0.020 |
Why?
|
Keratins | 1 | 2007 | 497 | 0.020 |
Why?
|
Nose | 1 | 2009 | 511 | 0.020 |
Why?
|
Specimen Handling | 1 | 2010 | 700 | 0.020 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2009 | 319 | 0.020 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2007 | 251 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12455 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 13553 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2008 | 977 | 0.020 |
Why?
|
Mice, SCID | 1 | 2009 | 2617 | 0.010 |
Why?
|
Phylogeny | 1 | 2012 | 2755 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 4110 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2011 | 1868 | 0.010 |
Why?
|
Child, Preschool | 3 | 2013 | 41659 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2625 | 0.010 |
Why?
|
Embryonic Stem Cells | 1 | 2009 | 1267 | 0.010 |
Why?
|
Benzamides | 1 | 2008 | 1364 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2009 | 1337 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2011 | 2224 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10797 | 0.010 |
Why?
|
Cell Differentiation | 2 | 2010 | 11422 | 0.010 |
Why?
|
Central Nervous System | 1 | 2008 | 1331 | 0.010 |
Why?
|
Mucous Membrane | 1 | 2004 | 654 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 29705 | 0.010 |
Why?
|
Up-Regulation | 1 | 2010 | 4115 | 0.010 |
Why?
|
Phenotype | 2 | 2011 | 16439 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2011 | 2895 | 0.010 |
Why?
|
Mast Cells | 1 | 2007 | 1432 | 0.010 |
Why?
|
Research Design | 2 | 2010 | 6116 | 0.010 |
Why?
|
Time Factors | 2 | 2013 | 39854 | 0.010 |
Why?
|
Captopril | 1 | 2000 | 264 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2005 | 1114 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2000 | 11830 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 4279 | 0.010 |
Why?
|
Cell Movement | 1 | 2011 | 5172 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15645 | 0.010 |
Why?
|
Radiosurgery | 1 | 2008 | 1335 | 0.010 |
Why?
|
Child | 3 | 2013 | 78998 | 0.010 |
Why?
|
Heart | 1 | 2012 | 4374 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13402 | 0.010 |
Why?
|
Angiotensin II | 1 | 2000 | 853 | 0.010 |
Why?
|
Sample Size | 1 | 2000 | 835 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 6964 | 0.010 |
Why?
|
Rhytidoplasty | 1 | 1998 | 63 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2004 | 1247 | 0.010 |
Why?
|
Genetic Variation | 1 | 2012 | 6507 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8538 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 25535 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2000 | 1687 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4067 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9429 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2007 | 3669 | 0.010 |
Why?
|
Survival Rate | 1 | 2009 | 12746 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21841 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3107 | 0.010 |
Why?
|
Prospective Studies | 2 | 2015 | 53807 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15506 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 18915 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2000 | 1515 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 3374 | 0.010 |
Why?
|
Carcinoma | 1 | 2004 | 2340 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2000 | 6482 | 0.010 |
Why?
|
Transcription Factors | 1 | 2009 | 12060 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3686 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 40984 | 0.010 |
Why?
|
Infant | 1 | 2012 | 35673 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13900 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2007 | 6306 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2005 | 10358 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15621 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2009 | 25914 | 0.010 |
Why?
|
Patient Selection | 1 | 2000 | 4238 | 0.000 |
Why?
|
Odds Ratio | 1 | 2000 | 9701 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39079 | 0.000 |
Why?
|
Pregnancy | 1 | 2009 | 29439 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2000 | 12326 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2013 | 79127 | 0.000 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2000 | 10198 | 0.000 |
Why?
|
Mice | 1 | 2009 | 80543 | 0.000 |
Why?
|
Animals | 1 | 2009 | 166802 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1998 | 15437 | 0.000 |
Why?
|